v3 Template
I

Incannex Healthcare Inc.

Healthcare / Biotechnology New York and Melbourne, Australia ~220 employees
Founded
--
Employees (Est.)
~220
11 leaders known
Total Funding
$633.9M
Funding Rounds
13
Last Funding
2025-07-24

About Incannex Healthcare Inc.

Incannex Healthcare is a science-led combination medicines company focused on developing novel oral fixed-dose treatments and therapeutic regimens for people with chronic conditions such as obstructive sleep apnea, rheumatoid arthritis, and generalized anxiety disorder.

Products & Services

IHL-42X:An oral fixed-dose combination of dronabinol and acetazolamide for obstructive sleep apnea (OSA), targeting intermittent hypoxia and hypercapnia. Currently in Phase 2/3 trials with dosing started in May 2024.
IHL-675A:An oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate for rheumatoid arthritis, aimed at reducing inflammation. Phase 2 dosing started in January 2024.
PSX-001:An oral synthetic psilocybin drug candidate for generalized anxiety disorder (GAD), administered with psychotherapy. Phase 2 trials ongoing with dosing completed for PsiGAD1 in January 2024.

Specialties

Combination Medicines Oral Fixed-Dose Treatments Chronic Conditions Obstructive Sleep Apnea Rheumatoid Arthritis Generalized Anxiety Disorder Synthetic Cannabinoids Psilocybin Therapy

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: At-The-Market (ATM) Offering
T: -
FT: At-The-Market (ATM) Offering
A: 100000000
MR: -
FA: $100 million
FAN: 100000000
D: 2025-07-24
FD: 2025-07-24
2 investors
2 RT: ATM
T: -
FT: ATM
A: 12200000
MR: -
FA: 12.2 million
FAN: 12200000
D: 2025-06-12
FD: 2025-06-12
-
3 RT: At-the-Market Facility
T: -
FT: At-the-Market Facility
A: 16700000
MR: -
FA: 16.7M
FAN: 16700000
D: 2025-05-20
FD: 2025-05-20
-
4 RT: At-the-Market (ATM) Offering
T: -
FT: At-the-Market (ATM) Offering
A: 12500000
MR: -
FA: $12.5M
FAN: 12500000
D: 2025-05-20
FD: 2025-05-20
1 investors
5 RT: Private Placement
T: -
FT: Private Placement
A: 12500000
MR: -
FA: 12.5 million
FAN: 12500000
D: 2025-03-07
FD: 2025-03-07
1 investors
6 RT: Convertible Note and Equity Line of Credit
T: -
FT: Convertible Note and Equity Line of Credit
A: 60000000
MR: -
FA: Up to 60,000,000 USD
FAN: 60000000
D: 2024-09-10
FD: 2024-09-10
2 investors
7 RT: Convertible Notes and Equity Line of Credit
T: -
FT: Convertible Notes and Equity Line of Credit
A: 60000000
MR: -
FA: $60 million
FAN: 60000000
D: 2024-09-10
FD: 2024-09-10
2 investors
8 RT: Convertible Debt and Equity Line of Credit
T: -
FT: Convertible Debt and Equity Line of Credit
A: 60000000
MR: -
FA: 60,000,000 USD
FAN: 60000000
D: 2024-09-10
FD: 2024-09-10
2 investors
9 RT: Convertible Debt and Line of Credit
T: -
FT: Convertible Debt and Line of Credit
A: 60000000
MR: -
FA: up to 60 million USD
FAN: 60000000
D: 2024-09-10
FD: 2024-09-10
2 investors
10 RT: Convertible Notes and Equity Line of Credit (ELOC)
T: -
FT: Convertible Notes and Equity Line of Credit (ELOC)
A: 60000000
MR: -
FA: $60 million
FAN: 60000000
D: 2024-09-10
FD: 2024-09-10
2 investors
11 RT: Debt and Equity Line of Credit
T: -
FT: Debt and Equity Line of Credit
A: 60000000
MR: -
FA: up to $60 million
FAN: 60000000
D: 2024-09-10
FD: 2024-09-10
2 investors
12 RT: Debt
T: -
FT: Debt
A: 60000000
MR: -
FA: 60 million
FAN: 60000000
D: 2024-09-10
FD: 2024-09-10
2 investors
13 RT: Debt and Equity Financing
T: -
FT: Debt and Equity Financing
A: 60000000
MR: -
FA: 60 million dollars
FAN: 60000000
D: 2024-09-10
FD: 2024-09-10
2 investors
At-The-Market (ATM) Offering Latest
2025-07-24
$100.0M
2 investors (Pro only)
ATM 2025-06-12
$12.2M
At-the-Market Facility 2025-05-20
$16.7M

View 12 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

J

Joel Latham

President and Chief Executive Officer

J

Joseph Swan

Chief Financial Officer

L

Lou Barbato

Chief Medical Officer

M

Mark Bleackley

Chief Scientific Officer

L

Lekhram Changoer

Chief Technology Officer

P

Parisa Asvadi

Vice President, Research and Development

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

Incannex Healthcare Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Healthcare / Biotechnology
Company Size
~220 employees (est.)
Locations
New York and Melbourne, Australia
Melbourne, Australia and New York
New York, USA and Melbourne, Australia

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro